Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2022; 76(6): 515–516. doi: 10.48095/ccgh2022515.

Dificlir – fidaxomicin – an effective treatment option for C. difficile infections in children

Kristýna Zárubová1

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Polage CR, Solnick JV, Cohen SH. Nosocomial diarrhea: evaluation and treatment of causes other than Clostridium difficile. Clin Infect Dis 2012; 55(7): 982–989. doi: 10.1093/cid/cis 551.
2. Noor A, Krilov LR. Clostridium difficile Infection in Children. Pediatr Ann 2018; 47(9): e359–e365. doi: 10.3928/ 19382359-20180803-01.
3. Banaszkiewicz A, Kowalska-Duplaga K, Pytrus T et al. Clostridium difficile infection in newly dia­gnosed pediatric patients with inflammatory bowel disease: prevalence and risk factors. Inflamm Bowel Dis 2012; 18(5): 844–848. doi: 10.1002/ibd.21837.
4. Tai E, Richardson LC, Townsend J et al. Clostridium difficile infection among children with cancer. Pediatr Infect Dis J 201; 30(7): 610–612. doi: 10.1097/INF.0b013e31820970d1.
5. Bagdasarian N, Rao K, Malani PN. Dia­g­nosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 2015; 313(4): 398–408. doi: 10.1001/jama.2014.17103.
6. Johnson S, Lavergne V, Skinner AM et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis 2021; 73(5): e1029–e1044. doi: 10.1093/cid/ciab549.
7. Beneš J, Stebel R, Musil V et al. Aktualizovaný doporučený postup pro léčbu nemocných s kolitidou vyvolanou Clostridioides difficile. Doporučený postup Společnosti infekčního lékařství ČLS JEP. 2022 [online]. Dostupné z: https://www.infektologie.cz/zprava22-39.htm.
8. Dificlir, souhrn údajů o přípravku. 2022 [online]. Dostupné z: https: //www.ema.europa.eu/documents/product-information/dificlir-epar-product-information_cs.pdf.
9. O‘Gorman MA, Michaels MG, Kaplan SL et al. Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical Trial. J Pediatric Infect Dis Soc 2018; 7(3): 210–218. doi: 10.1093/jpids/pix037.
10. Wolf J, Kalocsai K, Fortuny C et al. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE). Clin Infect Dis 2020; 71(10): 2581–2588. doi: 10.1093/cid/ciz1149.

Credited self-teaching test